Net sales

JPY 611.9 billion, mostly unchanged year on year.

Food Segment: Decreased 2% YoY

Pharmaceutical Segment:

   Increased 13% YoY, recorded strong growth

 ▸ Consolidated KM Biologics in Q2

 ▸ Covered decreased revenue from Food Segment

Operating income

JPY 43.8 billion, decreased 3% YoY

Exceeded plans revised in August (JPY 41.0 billion)

Extraordinary income

JPY 6.4 billion, gain on sales of fixed asset

JPY 6.5 billion, negative goodwill raised from KM Biologics

Extraordinary losses

Posted JPY 4.1 billion

Including JPY 1.0 billion, damage and loss due to earthquake, heavy rain and strong typhoon

Net income

JPY 38.3 billion, significant increase YoY